[1] WARREN D HIRST. Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue[J]. British Journal of Pharmacology, 2009, 130 7: 1597-1605. DOI:
10.1038/sj.bjp.0703458[2] CAROL ROUTLEDGE. Characterization of SB-271046: A potent, selective and orally active 5-HT6 receptor antagonist[J]. British Journal of Pharmacology, 2009, 130 7: 1606-1612. DOI:
10.1038/sj.bjp.0703457[3] AYAKA TATARA. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders[J]. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2012, 38 2: Pages 252-259. DOI:
10.1016/j.pnpbp.2012.04.008[4] FANNY DUHR. Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth[J]. Nature chemical biology, 2014, 10 7: 590-597. DOI:
10.1038/nchembio.1547[5] SAKI SHIMIZU. Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice[J]. Journal of pharmacological sciences, 2015, 127 4: Pages 439-445. DOI:
10.1016/j.jphs.2015.03.004 
